Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure
Study context
- Population
- Adults with T2D without known HF; mean age 62, 17% female
- Participants
- 62 adults
- Comparison
- Dapagliflozin 10 mg daily vs placebo for 12 months
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Systemic inflammation markers, baseline to 12 months
Plasma IL-1B change with dapagliflozin
- 1.8 pg/mL
P = 0.003
Ketone change with dapagliflozin
0.26 mM
P = 0.0001
PBMC maximal oxygen consumption rate (OCR) change with placebo
- 158.9 pmole/min/106 cells
P = 0.0497
PBMC maximal OCR change with dapagliflozin
- 5.2 pmole/min/106 cells
P = 0.41
Further findings
Global myocardial strain, ECV and T2 relaxation time (cardiac magnetic resonance imaging (CMRI)) · 12 months
- Did not change in both study groups
Original publication
Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure. Cardiovasc Diabetol. Published 7 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →